Pharma and Biotech M&A Deals Reached Record $212 Billion in 2014

EP Vantage 2014 in Review report shows sector eclipsed $152 billion raised in 2009, the year of the mega merger

20-Mar-2015 - Despite a slight wobble in the spring, the pharma and biotech sector came back stronger than ever in 2014, racking up a record-breaking $212 billion in M&A transactions. The feel good factor also extended to IPOs. Largely fueled by investor appetite for immunotherapy, 2014 boasted 87 flotations, ...

Innovation Driving Positive Outlook for Pharma and Biotech in 2015

Blockbuster launches, new indications and lack of patent expiries key to sector growth

12-Dec-2014 - Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year according to EP Vantage’s latest report, “Pharma & Biotech 2015 Preview.” EP Vantage is the editorial arm of market intelligence firm Evaluate Ltd.Key findings: A dozen products ...

New Report Shows Orphan Drug Market to Reach $176 Billion by 2020

Growth set to be nearly double that of overall prescription market excluding generics

31-Oct-2014 - In 2020 orphan drugs are expected to account for 19 percent of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to the new “EvaluatePharma® Orphan Drug Report 2014” from Evaluate Ltd.At 11 percent, growth in the orphan drug market is ...

Worldwide Prescription Drug Sales to Exceed Trillion Dollar Mark by 2020

Industry to grow, on average, 5.1 percent per year from 2013 to 2020

26-Jun-2014 - Record breaking new drug approvals, a hefty product pipeline and dramatically improved R&D productivity that has kept expenditure growth below sales growth prove that the industry is turning a new corner according to Evaluate’s, “World Preview 2014, Outlook to 2020” report.“This much improved ...

Sanofi Tops Pfizer As Number One For Global Pharma Sales

08-Nov-2011 - EvaluatePharma Ltd revealed that Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012 and hold it through 2016. The French drug maker has raced up the rankings over the last decade largely through M&A activity, with the $20bn purchase this year of US ...